Table 1

Baseline characteristics of postmyocardial infarction patients with rheumatoid arthritis and reference population

Rheumatoid arthritisReference
n=877n=65 230
Women514 (58.6)24 076 (36.9)
Men363 (41.4)41 154 (63.1)
Age (mean (SD))72.6 (11.0)69.5 (13.5)
Socio-economic status (mean (SD))2.79 (1.42)3.00 (1.41)
Pharmacotherapy
Aspirin236 (26.9)16 383 (25.1)
β-Blockers211 (24.1)14 672 (22.5)
Clopidogrel29 (3.3)1 412 (2.2)
RAS Blockers286 (32.6)18 911 (29.0)
Statins165 (18.8)12 849 (19.7)
Loop diuretics252 (28.7)11 913 (18.3)
Thiazides195 (22.2)12 266 (18.8)
Aldosteron antagonists56 (6.4)2706 (4.2)
Calcium blockers156 (17.8)10 465 (16.0)
Vitamin K antagonists53 (6.0)3157 (4.8)
Previous DMARD treatment706 (80.5)314 (0.5)
Comorbidity
Shock6 (0.6)276 (0.4)
Diabetes with complications38 (4.3)3 383 (5.2)
Congestive heart failure31 (3.5)753 (1.2)
Cancer95 (10.8)6 323 (9.7)
Cerebro-vascular disease151 (17.2)8 621 (13.2)
Pulmonary oedema12 (1.3)851 (1.3)
Acute renal failure19 (2.2)1 255 (1.9)
Chronic renal failure25 (2.8)1 688 (2.6)
Cardiac dysrhythmia187 (21.3)10 657 (16.3)
  • Values are numbers (%) unless otherwise stated.

  • DMARD, disease-modifying antirheumatic drugs; RAS, renin angiotenin system.